Tigecycline: a novel glycylcycline antibiotic

References

• Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg. Infect. Dis. 7, 188–192 (2001).
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Fraser GL, Stogsdill P, Society of Infectious Diseases Pharmacists. Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 24, 896–908 (2004).
   PubMedGoogle Scholar
• Diekema DJ, BootsMiller BJ, Vaughn TE et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. 38, 78–85 (2004).
   PubMed Web of Science ®Google Scholar
• Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J. Antimicrob. Chemother. 46(Suppl. T1), 3–9 (2000).
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309–317 (2004).
   PubMed Web of Science ®Google Scholar
• Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin. Infect. Dis. 39, 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289, 885–888 (2003).
   PubMed Web of Science ®Google Scholar
• Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development. Clin. Infect. Dis. 31, 1279–1286 (2004).
   Google Scholar
• Gales AC, Jones RN, Pfaller MA, Gordon KA, Sader HS. Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997–98. SENTRY Study Group. Int. J. Infect. Dis. 4, 75–84 (2000).
   PubMedGoogle Scholar
• Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). SENTRY study group (North America). Diagn. Microbiol. Infect. Dis. 34, 65–72 (1999).
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352, 1436–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus – New York, 2004. Morb. Mortal. Wkly Rep. 53, 322–323 (2004).
   PubMedGoogle Scholar
• Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. 7, 327–332 (2001).
   PubMed Web of Science ®Google Scholar
• Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 64, 1621–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37, 997–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Hunter PA, Castaner J. GAR-936. Drugs Future 26, 851–858 (2001).
   Google Scholar
• Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 47, 665–669 (2003).
   PubMed Web of Science ®Google Scholar
• Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47, 972–978 (2003).
   PubMed Web of Science ®Google Scholar
• Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. 1, 464–469 (2001).
   PubMedGoogle Scholar
• Bouchillon SK, Hoban DJ, Johnson BM et al. In vitro activity of tigecycline against 3,989 Gram-negative and Gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program; 2004). Diagn. Microbiol. Infect. Dis. 52, 173–179 (2005).
   PubMed Web of Science ®Google Scholar
• Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J. Antimicrob. Chemother. 52, 138–139 (2003).
   PubMed Web of Science ®Google Scholar
• Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin. Ther. 27, 12–22 (2005).
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST program, 2004). Diagn. Microbiol. Infect. Dis. 52, 215–227 (2005).
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52, 181–186 (2005).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia pathogens. Diagn. Microbiol. Infect. Dis. 52, 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Stillwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004). Diagn. Microbiol. Infect. Dis. 52, 195–201 (2005).
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care units Diagn. Microbiol. Infect. Dis. 52, 203–208 (2005).
   PubMed Web of Science ®Google Scholar
• Kitzis MD, Ly A, Goldstein FW. In vitro activities of tigecycline (GAR-936) against multi-drug resistant Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48, 366–367 (2004).
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis. 50, 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38, 177–179 (2000).
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 143, 738–744 (1999).
   Google Scholar
• Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a critical review. Drugs 64, 63–88 (2004).
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic- resistant Gram-positive bloodstream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 40, 173–177 (2001).
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Hoban DJ, Johnson M et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001–2002. Diagn. Microbiol. Infect. Dis. 51, 291–295 (2005).
   PubMed Web of Science ®Google Scholar
• Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49, 479–487 (2002).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones JN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn. Microbiol. Infect. Dis. 52, 209–213 (2005).
   PubMed Web of Science ®Google Scholar
• Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47, 400–404 (2003).
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48, 4479–4481 (2004).
   PubMed Web of Science ®Google Scholar
• Tygacil™ (tigecycline) package label. Wyeth Pharmaceuticals, Inc., PA, USA.
   Google Scholar
• Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr. Pharm. Des. 4, 119–132 (1998).
   PubMed Web of Science ®Google Scholar
• Sum PE, Petersen P. Synthesis and structure–activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9, 1459–1462 (1999).
   PubMed Web of Science ®Google Scholar
• Bronson JJ, Barrett JF. Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and cephem antibacterials in clinical development. Curr. Med. Chem. 8, 1775–1793 (2001).
   PubMedGoogle Scholar
• Fluit AC, Florijn A, Verhoef J et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob. Agents Chemother. 49, 1636–1638 (2005).
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43, 738–744 (1999).
   PubMed Web of Science ®Google Scholar
• Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20, 219S–223S (2000).
   PubMed Web of Science ®Google Scholar
• Bergeron J, Ammirati M, Danley D et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. 40, 2226–2228 (1996).
   PubMed Web of Science ®Google Scholar
• Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Chemother. 38, 1658–1660 (1994).
   PubMed Web of Science ®Google Scholar
• Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulfate and drug-directed Fe2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53, 592–599 (2004).
   PubMed Web of Science ®Google Scholar
• Someya Y, Yamaguchi A, Sawai T. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob. Agents Chemother. 39, 247–249 (1995).
   PubMed Web of Science ®Google Scholar
• McAleese F, Petersen P, Ruzin A et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob. Agents Chemother. 49, 1865–1871 (2005).
   PubMed Web of Science ®Google Scholar
• Hirata T, Saito A, Nishino K, Tamura N, Yamaguchi A. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob. Agents Chemother. 48, 2179–2184 (2004).
   PubMed Web of Science ®Google Scholar
• Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 49, 1017–1022 (2005).
   PubMed Web of Science ®Google Scholar
• Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob. Agents Chemother. 49, 791–793 (2005).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Johanson C, Embil JM et al. Ertapenem: review of a new carbapenem. Expert. Rev. Anti Infect. Ther. 3(1), 23–39 (2005).
   PubMedGoogle Scholar
• Zhanel GG, Schroeder K, Vercaigne L, Gin AS, Embil J, Hoban DJ. A critical review of oxazolidinones: a replacement for glycopeptides? Can. J. Infect. Dis. 12, 379–390 (2001).
   PubMedGoogle Scholar
• Zhanel GG, Simor AE, Vercaigne L, Mandell L, and the Canadian Carbapenem Discussion Group. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can. J. Infect. Dis. 9, 215–228 (1998).
   PubMedGoogle Scholar
• Zhanel GG, Ennis K, Vercaigne L et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 62, 13–59 (2002).
   PubMedGoogle Scholar
• Betriu C, Rodriguez-Avial I, Sanchez BA et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46, 892–895 (2002).
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against Gram-positive bacteria. Antimicrob. Agents Chemother. 44, 2225–2229 (2000).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int. J. Antimicrob. Agents 24, 567–571 (2004).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn. Microbiol. Infect. Dis. 49, 201–209 (2004).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36, 19–36 (2000).
   PubMed Web of Science ®Google Scholar
• Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44, 1085–1088 (2000).
   PubMed Web of Science ®Google Scholar
• Low DE, Kreiswirth BN, Weiss K, Willey BM. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int. J. Antimicrob. Agents 20, 220–222 (2002).
   PubMedGoogle Scholar
• Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob. Agents Chemother. 46, 2595–2601 (2002).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, Bellvou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibility study, 1997–2002. Antimicrob. Agents Chemother. 47, 1867–1874 (2003).
   PubMed Web of Science ®Google Scholar
• Betriu C, Gomez M, Rodriguez-Avial I, Culebras E, Picazo JJ. In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates. J. Antimicrob. Chemother. 55, 809–810 (2005).
   PubMedGoogle Scholar
• Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Picazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 50, 758–759 (2002).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ, and the CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47, 1875–1881 (2003).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Laing NM, Weshnoweski BJ et al. Activity of tigecycline against fluoroquinolone (FQ) resistant out-patient urinary isolates of Escherichia coli in North America: Results from the North American Urinary Tract Infection Collaborative Alliance – Quinolone Resistant (NAUTICA-QR). Proceeding of the 45th Interscience Conference on Chemotherapy and Antimicrobial Agents. LA, USA, C2-1214 (2005).
   Google Scholar
• Reese AM, Burgess DS. In vitro pharmacodynamics and post-antibiotic effects (PAE) of tigecycline against Gram-negative bacteria. Proceeding of the 45th Interscience Conference on Chemotherapy and Antimicrobial Agents. LA, USA, A-1821 (2005).
   Google Scholar
• Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 48, 1034–1036 (2004).
   PubMed Web of Science ®Google Scholar
• Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin. Microbiol. Infect. 6, 159–163 (2000).
   PubMedGoogle Scholar
• Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob. Agents Chemother. 44, 2747–2751 (2000).
   PubMed Web of Science ®Google Scholar
• Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea-pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 47, 533–540 (2003).
   PubMed Web of Science ®Google Scholar
• Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45, 2604–2608 (2001).
   PubMed Web of Science ®Google Scholar
• Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int. J. Antimicrob. Agents 16, 61–63 (2000).
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Jones RN. In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn. Microbiol. Infect. Dis. 42, 145–147 (2002).
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46, 3164–3167 (2002).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Brunham RC. Third-generation cephalosporins. Can. J. Hosp. Pharm. 41, 183–194 (1988).
   Google Scholar
• Majumdar AK, Musson DG, Birk K et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. 46, 3506–3511 (2002).
   PubMed Web of Science ®Google Scholar
• Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A), 39–60 (1993).
   PubMed Web of Science ®Google Scholar
• Levaquin® (levofloxacin in 5% dextrose) injection package label. Ortho-McNeil Pharmaceutical, Inc., NJ, USA.
   Google Scholar
• Zyvox® (linezolid) package label. Pharmacia & Upjohn, Division of Pfizer, Inc., NY, USA.
   Google Scholar
• Vancocin® HCL (vancomycin injection, USP) package label. Eli Lilly and Company. Baxter Healthcare Corporation, IL, USA.
   Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 49, 220–229 (2005).
   PubMed Web of Science ®Google Scholar
• Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, A-1403 (2002).
   Google Scholar
• Sun HK, Ong CT, Umer A et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. 49, 1629–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Rodvold KA, Cwik M et al. An open-label clinical evaluation of tigecycline (TGC) concentrations in selected tissues and fluids. Proceedings of the American Society for Clinical Therapeutics and Pharmacology. Brisbane, Australia, 05-LB-551-ASCPT (2004).
   Google Scholar
• Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents 25, 523–529 (2005).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M et al. Tigecycline (TGC) concentrations (Cp) in lung tissue, cerebrospinal fluid (CSF), and bile of human subjects. Proceeding of the 45th Interscience Conference on Chemotherapy and Antimicrobial Agents. LA, USA, A-18 (2005).
   Google Scholar
• Hoffman H, DeMaio W, Jordan RA et al. Metabolic disposition of [14C]tigecycline in human volunteers following intravenous infusion. Proceedings of the American Association of Pharmaceutical Scientists. MD, USA, 2540 (2004).
   Google Scholar
• Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob. Agents Chemother. 49, 1656–1659 (2005).
   PubMed Web of Science ®Google Scholar
• Troy SM, Muralidharan G, Micalizzi M et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, A-43 (2003).
   Google Scholar
• Zimmerman JJ, Harper D, Matschke K, Speth J, Raible DG, Fruncillo RJ. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 1306 (2004).
   Google Scholar
• Nicolau DP. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother. 9, 292–296 (2003).
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1–10 (1998).
   PubMed Web of Science ®Google Scholar
• van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 44, 943–949 (2000).
   PubMed Web of Science ®Google Scholar
• Lefort A, Lafaurie M, Massias L et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 47, 216–222 (2003).
   PubMed Web of Science ®Google Scholar
• Postier RG, Green SL, Klein SR et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. 26, 704–714 (2004).
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41(Suppl. 5), S341–353 (2005).
   PubMed Web of Science ®Google Scholar
• Murray J, Wilson S, Klein S et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase 2 clinical trial. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, L-739 (2003).
   Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5), S354–S367 (2005).
   PubMed Web of Science ®Google Scholar